Microglia depletion restored two hours of sleep in Alzheimer's mice without clearing amyloid plaques

A team at the University of Kentucky has shown that sleep loss linked to Alzheimer's pathology can be reversed without touching the disease's hallmark amyloid plaques. According to ScienceDaily, mice engineered to develop plaque buildup recovered more than two additional hours of sleep per day after researchers temporarily removed most of their microglia, the brain's resident immune cells. The study appears in the journal Alzheimer's & Dementia and was led by Shannon L. Macauley, an associate professor of physiology at the university's College of Medicine, with recent doctoral graduate Nicholas J. Constantino as first author.

A shift in what gets blamed for sleep loss

Sleep disruption in Alzheimer's has traditionally been attributed mainly to damaged neurons or to the plaques themselves. The Kentucky results point elsewhere: when microglia detect plaques, their defensive reaction releases inflammatory signals that interfere with normal brain activity, and that cascade — not plaque mass or neuronal dysfunction alone — appears to drive the sleep loss. Macauley characterised the finding as overturning the field's prevailing model of why Alzheimer's patients sleep so poorly. The researchers compare the immune response to a sprinkler system that floods an entire building over a small kitchen fire: the defence mechanism ends up causing more disruption than the original threat.

How the experiments were run

The scientists worked with two mouse populations — one genetically predisposed to amyloid plaques and one normal wild-type group — and examined both at six months, when plaques first emerge in the modified animals, and at 18 months, when pathology is more advanced. Comparing the groups separated Alzheimer's-related changes from ordinary brain ageing. Head-mounted devices recorded EEG and EMG signals to classify sleep stages, while light-sheet microscopy rendered tissue transparent and produced three-dimensional maps showing where plaques and microglia sat relative to each other across whole brains.

To test whether microglia were actually responsible, the team fed the animals pexidartinib (PLX3397), a compound originally developed for cancer research that blocks a survival signal the immune cells depend on. After fourteen days, roughly 87 percent of the microglia had been depleted. The mice then slept longer and spent more time in deep, restorative sleep. A mathematical method called FOOOF, which splits rhythmic brain waves from background electrical noise, indicated the cortex no longer stayed unusually active when it should have been resting.

Plaque load and sleep loss do not track together

The most counterintuitive result concerned plaque accumulation. The group had expected sleep to deteriorate as plaques multiplied; instead, disruption was already substantial at six months and remained largely unchanged at 18 months even though plaque burden had more than doubled. Constantino, who had anticipated a straightforward relationship between plaque severity and sleep disturbance, noted that the early changes simply held steady as pathology advanced. The team describes this as a ceiling effect: the initial inflammatory response to plaques appears to do most of the damage, and further plaque growth adds little additional sleep loss. That pattern could help explain why sleep problems often show up early in the disease course.

Why it matters

Sleep disturbance is among the most disruptive symptoms of Alzheimer's, and this work decouples it from the amyloid-clearance question that dominates drug development. If immune-driven inflammation rather than plaque volume drives the sleep loss, symptoms could in principle be treated independently of anti-amyloid therapies, and microglia modulation becomes a therapeutic target in its own right. The caveats are real: these are mouse findings, wholesale microglia depletion is a research tool rather than a clinical strategy, and nothing has yet been demonstrated in humans. Even so, the study reframes a familiar and draining symptom as potentially reversible, and it identifies a mechanism future treatments could aim at far more precisely than blanket immune-cell removal ever could.